Key points are not available for this paper at this time.
Dual RAS blockade reduces proteinuria but not ESRD, mortality, or CV events in DKD; raises hyperkalemia and AKI risks, reinforcing monotherapy preference.
Objective: There is substantial evidence for a renoprotective effect of inhibitors of the renin-angiotensin system (RAS) in diabetic kidney disease (DKD). However, it is unclear whether dual RAS blockade has additional benefits when compared to monotherapy in this population and whether any benefits outweigh the risks.
No takes yet. Share an insight, caveat, or question.
Jacqueline T. Pham (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: